Alliqua’s MIST wound-care system eligible for Medicare coverage in FL, Caribbean territories

Alliqua BioMedical ($ALQA) announced its MIST ultrasound wound-care system is now covered by Medicare Administrative Contractor First Coast Service Options, which processes claims in Florida, Puerto Rico and the U.S. Virgin Islands.

First Coast, which is one of 8 regional Medicare contractors in the U.S., covers a region that represents more than 58,000 providers and about 2.9 million Medicare beneficiaries, the company said.

The FDA-approved MIST Therapy System uses a low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. With the addition of First Coast, Medicare coverage for MIST now includes all Medicare Administrative Contractors.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

“I believe that our success in obtaining nationwide Medicare reimbursement coverage is largely attributable to the compelling portfolio of clinical support for our innovative MIST Therapy, which demonstrates the System’s effectiveness in accelerating the wound healing process,” Nino Pionati, chief strategy and marketing officer of Alliqua, said in a statement.

Langhorne, PA-based Alliqua picked up the MIST system in early 2015 when it shelled out $30.4 million to acquire Celleration in an effort to expand its presence in regenerative medicine.

A couple of months after the Celleration deal, Alliqua upped its exclusive licensing agreement with Celgene Cellular Therapeutics, a subsidiary of Celgene ($CELG), to add the right to develop and market the biopharma's connective tissue matrix (CTM) product.

Suggested Articles

Medtronic has moved to acquire Avenu Medical, developers of a minimally invasive method of building the blood vessel access ports.

The agency also gave the company’s diagnostic, run on the high-throughput Panther Fusion laboratory platform, a green light for pooled testing.

Smith & Nephew has signed up to acquire Integra LifeSciences’ orthopedics business focused on the growing upper and lower extremity markets.